Developmental expression and localization of glycogen synthase kinase-3β in rat brain
|
journal
|
June 1999 |
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder
|
journal
|
January 2007 |
Design of potent and selective GSK3β inhibitors with acceptable safety profile and pharmacokinetics
|
journal
|
April 2010 |
GSK-3 as potential target for therapeutic intervention in cancer
|
journal
|
May 2014 |
GSK-3β and memory formation
|
journal
|
January 2012 |
GSK-3 inhibition by an orally active small molecule increases bone mass in rats
|
journal
|
March 2012 |
Chapter 1 Recent Advances in the Discovery of GSK-3 Inhibitors and a Perspective on their Utility for the Treatment of Alzheimer's Disease
|
book
|
January 2009 |
A quantitative analysis of kinase inhibitor selectivity
|
journal
|
January 2008 |
What Are the bona fide GSK3 Substrates?
|
journal
|
January 2011 |
Microtubule-based intracellular transport of organelles
|
book
|
January 1995 |
Functional Redundancy of GSK-3α and GSK-3β in Wnt/β-Catenin Signaling Shown by Using an Allelic Series of Embryonic Stem Cell Lines
|
journal
|
June 2007 |
6-Amino-4-(pyrimidin-4-yl)pyridones: Novel glycogen synthase kinase-3β inhibitors
|
journal
|
March 2011 |
GSK-3 mouse models to study neuronal apoptosis and neurodegeneration
|
journal
|
January 2011 |
Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy
|
journal
|
January 2009 |
Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes
|
journal
|
September 1999 |
Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats
|
journal
|
May 2003 |
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.
|
journal
|
July 1986 |
Pd-Catalyzed Intermolecular Amidation of Aryl Halides: The Discovery that Xantphos Can Be Trans-Chelating in a Palladium Complex
|
journal
|
May 2002 |
Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice
|
journal
|
October 2009 |
2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole Derivatives as Novel Inhibitors of Glycogen Synthase Kinase-3β with Good Brain Permeability
|
journal
|
September 2009 |
Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer’s Disease: Design, Synthesis, and Characterization of Pyrazines
|
journal
|
April 2012 |
Molecular cloning and expression of glycogen synthase kinase-3/factor A.
|
journal
|
August 1990 |
Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3β
|
journal
|
February 2004 |
Glycogen Synthase Kinase 3 (GSK‐3) and Its Inhibitors: Drug Discovery and Development
|
book
|
March 2006 |
Discoveries of Tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: A personal historical perspective
|
journal
|
July 2006 |
Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models
|
journal
|
January 2012 |
Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core
|
journal
|
May 2015 |
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
|
journal
|
September 2009 |
Aberrant Glycogen Synthase Kinase 3β Is Involved in Pancreatic Cancer Cell Invasion and Resistance to Therapy
|
journal
|
February 2013 |
Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain
|
journal
|
January 1997 |
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin
|
journal
|
September 2015 |
Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, That Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy
|
journal
|
October 2011 |
GSK-3: tricks of the trade for a multi-tasking kinase
|
journal
|
April 2003 |
Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib
|
journal
|
January 2012 |
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
|
journal
|
December 1995 |
Functional Implications of Glycogen Synthase Kinase-3-Mediated Tau Phosphorylation
|
journal
|
January 2011 |
2013 Alzheimer's disease facts and figures
|
journal
|
March 2013 |
Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway: Role of GSK-3β in Adult Brain
|
journal
|
January 2009 |
Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal
|
journal
|
July 2006 |
Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation: In vivo efficacy of GSK-3 inhibitors
|
journal
|
November 2007 |
A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease: Effects of a novel GSK-3 inhibitor MMBO in AD mice
|
journal
|
November 2011 |
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
|
journal
|
November 2001 |
Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
|
journal
|
December 2012 |
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
|
journal
|
May 1986 |